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Introduction
The Eastman Kodak Company has recently described a new
concept in clinical chemistry, namely the use of dry chemistry
films to be used initially for colorimetric analysis [2,3]. The
glucose and urea methods were evaluated in this study
following the guidelines by the National Committee for
Clinical Laboratory Standards (NCCLS) [1] which are
recommendations for goals to be sought by manufacturers.
This evaluation protocol is designed to provide a multi-
purpose evaluation framework for a wide range of methods
and instruments and is in three sections. PSEP-2 (proposed
standard for establishing performance claims) describes the
four-week baseline period which is used to establish
confidence limits for the controls used throughout the study.
PSEP-3 details the precision study and PSEP-4 describes the
comparison of methods experiment.
The Kodak Ektachem GLU/BUN analyser is a micro-
processor controlled discrete analyser which operates in
single or dual test mode. The instrument used in the present
study was an engineering model used in the USA and Europe
and was designed to evaluate the concept of quantitative
chemical analysis using multilayered reagents. It was used
according to the operators manual. The instrument was
modified to give urea values, as opposed to blood urea
nitrogen values, and was calibrated in mmol/L.
Methods and materials
NCCLS protocol for establishing performance claims for
clinical chemistry methods
The protocol is in three sections [1]. The sections and the
material used are described below.
Performance check experiment PSEP-2
The protocol describes control criteria which were established
for the test method. These criteria were used to control
performance of the Kodak test methods during the per-
formance of subsequent sections of the protocol. The control
sera used were lyophilised human material provided by Kodak
for the LOW and HIGH levels and Wellcomtrol II (Wellcome
Reagents Limited, Kent, UK) for the MID-level.
Replication experiment PSEP-3
The replication (imprecision) protocol specifies a period of
twenty days and a total of forty analytical runs. The ’midi’
version was chosen as it is designed for medium rate
automated methods. The midi experiment involves the
analysis of half the number of samples compared with the
maxi version, and unlike the mini experiment still enables
the effects of carryover to be investigated. For each con-
centration level studied two different estimates of within
run and total imprecision are required for presentation of
performance claims. The first, designated ’point estimate’,
is the actual standard deviation observed .in the experiment
performed and the second, designated ’tolerance limit’,
represents the upper limit that with 95% confidence will
contain the estimate of standard deviation from 99% of all
similar experiments.
The replication experiment used the .three controls from
the performance check period together with Pathonorm L
(PATH-L) from Nygaard, BDH, Poole, England; Wellcomtrol
(WELL-I) from Wellcome Reagents Limited, Beckenham,
England and GEO A632 from General Diagnostics, New
Jersey, USA. Lyophilised material was stored at 4C prior
to reconstitution on the morning of each experimental run.
Comparison of methods experiment PSEP-4
In this experiment a series of patient samples are analysed
by both the test method and a comparative analytical
method. A suggested concentration distribution of samples
for a number of analytes is given in the protocol. Table
gives the distribution suggested by the NCCLS in PSEP-4
and the actual distribution used for urea and glucose samples.
Patient samples were collected over four weeks prior to
the comparison of methods experiment. Serum samples for
urea and plasma samples (fluoride-oxalate anticoagulant)
for glucose were collected and stored at-20C. Each day
twenty-five samples were thawed and analysed as random
duplicates by the test and comparative methods. Analyses
were performed within two hours by both techniques, and
each set contained samples in all category levels.
Regression analysis on the data for each analyte used the
mean of paired duplicates. The comparative method was the
independent variable (X) and the Kodak Ektachem system
the dependent variable (Y). In order to illustrate the effect
of the advice given in the NCCLS protocol on preparation
of manufacturers claims three sets of data have been used
for regression analysis. Set e included results from all
samples. Set e2 excluded samples if the mean of any duplicate
by the Kodak Ektachem system was outside the dynamic
range specified in the operators manual [4], that is for
glucose 1.11-33.3 retool/1 and for urea 0.71-42.8 mmol/1,
or if the mean of any duplicate by the comparative method
was outside the manufacturers quoted dynamic range.
Set ea was prepared by using the standard error about the
regression line (Syx) calculated from data set e2 to apply the
test for outliers whereby up to three pairs showing a differ-
ence of greater than 3.5 times Syx can be excluded before
the final regression analysis. The number of pairs with a
difference in excess of 3.5 times Syx is given with all re-
gression statistics. The regression statistics obtained on data
set ea were used to calculate average bias (Yc-Xc, where
Yc is the test method value at medical decision concentration
Xc) at different medical decision concentrations,. Tolerance
limits were calculated for Yc so that there is a 99% probability
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that 95% of the sample results are included within the upper
and lower limits and total error was established as the absolute
value of the largest difference between the tolerance limits
and Xc. It is recommended that the tolerance limits and total
error be calculated only for the medical decision con-
centration closest to the mean of the comparative method
results. Evident non-linearity of the data must be assessed
visually in a scatter plot. It has been recommended [5] that
the linear-regression procedures used in this paper should be
restricted to those cases where the correlation coefficient (r)
exceeds 0.99. Similarly it has been suggested [6] that the
range of values used is adequate when the standard deviation
of the comparative method values (SDx) is greater than seven
times Syx. The correlation coefficient and the ratio SDx/Syx
are related [7]. With a slope of 1.00 and when the number of
pairs is 200 and SDx/Syx 7.0 then r 0.9900. Values for
both r and SDx/Syx are given with regression statistics. The
relationship between the two values is such that changes in
SDx/Syx are easier to observe.
Wellcome Group quality control programme
Samples previously sent out by the scheme from 16th
October 1978 to 26th March 1979 were analysed by the
comparative and Kodak methods. Two duplicate sets of
twelve lyophilised bovine sera were provided and a sample
for analysis taken from each of the twenty-four bottles
after reconstitution, giving twelve duplicate analyses for each
analyte.
Analysis of the twelve samples by participating laboratories
is normally spread over a six month period and the analysis
of results returned includes the overall mean for each analyte,
that is the mean of all results returned, with results greater
than three standard deviations from the mean excluded, and
method means which represent the mean of all results from
laboratories with a particular method classification.
Appropriate standard deviations are also provided. The over-
all mean values in the samples used ranged from 3.40 to
13.77 mmol/L for glucose and from 5.21 to 23.61 mmol/1
for urea.
Comparative analytical methods
Standard AutoAnalyzer (Technicon) methodologies were
used as the comparative methods. The diacetyl monoxime
reaction for urea employed aqueous urea standards, the
sample rate was 60/hour and samples with values above
20 mmol/1 were diluted one in five in deionised water. For
glucose the method was a glucose oxidase/peroxidase reaction
with phenol and aminoantipyrine. Standards were prepared
in saturated aqueous benzoic acid solution, the sample rate
was 60/hour and sera with values above 20 mmol/1 were
diluted one in five in deionised water.
Kodak methods
Details of the glucose and urea slide chemistry are described
by Curme et al 2] and Spay_d et al [3 ]. Cartridges containing
fifty slides were stored at 4C and allowed to warm to room
temperature for half an hour before the foil pack was opened.
All experimental work reported here employed one coating
batch, with daily calibration using three serum calibrators.
Two hundred microliter samples were used for all studies.
Samples with urea values above 40 mmol/1 were diluted one
in two with water.
Results
Performance check experiment (PSEP-2)
Baseline performance data for forty sets of triplicate deter-
minations over a twenty day period appear in Table 2, which
provided performance check parameters for the replication
and method comparison studies. Forty consecutive sets of
readings were found using the criteria in the protocol.
Performance during the rest of the study was assessed
by the mid control charts as described in the NCCLS protocol.
Charts were constructed for the high, mid and low controls.
The high and low control charts were only used as
corroborative evidence if an outlier occurred in the mid level
charts. Throughout the study there was only one mid control
outlier. One reading of a triplicate set produced a mean and
range error. However, the high and low control mean and
range charts were well within limits and so this run was not
rejected.
Replication experiment (PSEP-3)
Table 3 gives the analysis of variance (ANOVA) results for
the replication experiment. It should be noted that the
carryover effect on WELL-I for glucose and urea is based on
testing significant differences in variance with and without
Table 1. Distribution of samples for comparison of methods experiment
Glucose
Categories A B C D E
Range (mmol/1) --.2.8 2.9-6.1 6.2-8.3 8.4-13.8 13.8
Suggested sample distribution (%)* 10 40 30 10 10
Number of samples 20 80 40 20 40
% distribution achieved 10 40 20 10 20
Urea
Categories A B C D E
Range (mmol/1) /---.5.3 5.4-8.9
Suggested sample distribution (%)* 20 40
Number of samples 40 80
% distribution achieved 20 40
*NCCLS PSEP-4. See textfor discussion ofglucose distribution
9.0-17.9 18.0-35.6 >35.6
20 10 10
40 20 20
20 10 10
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carryover. Table 4 gives the claims for imprecision with and
without carryover following the NCCLS format.
Comparison of methods experiment (PSEP-4)
Figures and 2 give the regression statistics together with
correlation coefficient and the ratio SDx/Syx for patient
samples used in the comparison of methods experiment. The
preparation of data sets ez, e2 and e3 is described in the
Methods and Materials section. Regression statistics from
data set e3 were used to calculate the accuracy performance
claims given in Table 5.
Wellcome Group quality control programme
There were two main objectives in using the multi-level
lyophilised material available from the programme:
1. To provide additional information to that obtained in
the comparison of methods experiment and compare the
estimates from regression analysis with those calculated from
patient samples. No exclusion criteria were applied to these
results as the number of samples was very small. The ratio
SDx/Syx in every case was well in excess of 7.0 and no pairs
showed a difference in excess of 3.5 times Syx (Table 6 lines
(a) and (e)).
2. In studies involving comparison of methods, conclusions
concerning the performance of the test method are very
dependent on the performance of the comparative or
reference methods. Each comparative method can be classified
in the Wellcome Scheme and the results obtained in each
laboratory evaluated against the method mean (Table 6 lines
(c) and (g)). Additionally they can be evaluated against the
overall mean (Table 6 lines (d) and (h)).
The Kodak results are evaluated against the overall mean
as it is difficult to classify this methodology in the Wellcome
Scheme method classification (Table 6 lines (b) and (f)).
Discussion
The establishment of performance and claims for clinical
chemical methods has now become a major problem for
manufacturers of clinical chemistry systems and is in danger
of consuming a major part of a limited resource, namely that
of skilled laboratory workers.
In these activities however there are complex problems for
manufacturers and clinical chemistry laboratories alike and
the publication of proposed standards PSEP-2, 3 and 4 by
II
the NCCLS represents an important contribution to progress
in this field.
This paper and the subsequent one [8] reports some of
the authors’ experience with these standards and the data
derived from their work.The PSEP-2 and 3 standards although
time consuming present few difficulties in execution based
as they are on freeze dried material. However there are
difficulties in carrying out the proposed standard for the
Comparision of Methods Experiment (PSEP-4). The diffi-
culties relate on the one hand to the selection of patient
samples and their analysis according to the protocol and on
the other hand to the performance of the comparative
methods during the period of study.
The overview of the Comparison of Methods Experiment
suggests that "at least 100 fresh patients’ samples should_ be
analysed in duplicate by both the test method and the com-
parative analytical method. The experiment must cover a
period of at least four days which permits a maximum of
twenty-five samples to be analysed in one day, or it can
Table 2. Performance check period (PSEP-4)statistics
Glucose
Grand mean
Standard deviation (SD)
Control limits + 3 x SD
Mean range R
Control limits 2.57 R
Urea
Grand mean
Standard deviation (SD)
Control limits + 3 x SD
Mean range R
Control limits 2.57 R
Controls
Low
3.390
0.062
0.186
0.084
0.216
3.170
0.145
0.435
O.O8O
0.206
Medium
11.590
0.198
0.594
0.193
0.496
29.130
0.512
1.540
0.596
1.530
High
28.530
0.304
0.912
0.321
0.824
36.550
0.877
2.63
0.828
2.130
35
30
25
20,
15.
10-
5-
AAI (mmol/I)
Figure 1. Glucose Comparative Method (X) and Kodak
Ektachem (Y) for patient samples.
40-
o o :;) ’o ’o o’o ;o
AAI (mmol/I)
Figure 2. Urea Comparative Method (X) and Kodak
Ektachem (Y) for patient samples.
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extend over a longer period of time if that is convenient
for the evaluation study". Recommendations for the selection
of patients samples are given and one suggested distribution
is shown in Table 1.
The authors were only able to comply with the suggested
distribution by preselecting samples and freezing them prior
to subsequent duplicate analysis. The amount of sample
required to perform duplicate analysis by the test and com-
parative method represents a major problem if the test and/
or comparative methods require substantial amounts of
serum or plasma. The use of the NCCLS protocol for
evaluation of multichannel systems may present special
difficulties although one such evaluation has recently been
published [9].
A penalty of not running duplicates is the failure to
produce within run estimates of imprecision for human sera
for the test and comparative methods. The information is
important for evaluation of the comparative method and for
its comparison with the test method. Additionally these
estimates of within run imprecision can be usefully compared
with those obtained in the replication experiment using the
lyophilised material.
It was found that there was a tendency when selecting
samples for analysis to encounter difficulties at the ends of
the range. This could lead to the multiple selection of samples
from one patient so that although the number of samples
required is fulfilled the variability represented by those
samples is reduced. If this were to become a major feature of
selection then it might result in falsely low estimates of Syx
which would markedly improve the accuracy performance
claims. It is interesting in this conrtection to compare the
regression statistics for comparison of methods for the bovine
material from the Wellcome Scheme (Table 6 lines (a)and
(e)) with those obtained on patient samples (Figures and 2).
Bearing in mind the recognised problems associated with
commutability of samples and the small number of Wellcome
samples used the estimates of slope and intercept were in
agreement with those obtained with patient samples. However
the value for Syx for urea and glucose using Wellcome
material is markedly lower than the value for patient
samples. This reflects the fact the Wellcome material is
taken from only four homogenous pools and covers a smaller
range of analyte concentrations.
If in excess of fifty quality control samples were used in
a comparison of methods experiment and commutability
were satisfactory the standard deviation of the estimates of
slope and intercept would be markedly improved but analysis
of lyophilised material from different sources can never
replace patient samples in estimation of the standard error of
the regression line.
Table 4. Performance claims for imprecision with and without
carryover
Within run Total imprecision
imprecision
Concn Tolerance Tolerance
Serum mmol/1 SD limit SD limit
Glucose
Without carryover
Path-L 1.465 0.0226 0.0307 0.0735
WelM 6.257 0.0868 0.1180 0.1204
Geo A632 26.068 0.1834 0.2494 0.4637
With carryover
Path-L 1.470 0.0253 0.0344 0.0747 0.0964
WelM 6.293 0.1296 0.1762 0.1712 0.2208
Geo A632 26.063 0.1579 0.2147 0.4547 0.5866
Urea
Without carryover
Path-L 2.961 0.0378 0.0514 0.1210
Well-I 9.095 0.1215 0.1652 0.1920
Geo A632 31.761 0.4851 0.6597 0.5561
With carryover
Path-L 2.956 0.0327 0.0445 0.1214 0.1566
Well-I 9.069 0.1842 0.2505 0.2469 0.3185
Geo A632 31.777 0.4856 0.6604 0.5439 0.7016
Table 3. Analysis of variance (ANOVA) of data from four week precision study with and without effects of carryover
Components of variance
Within run Run-run Day-day Total
Conc SD CV (df) SD CV (df) SD CV (df) SD CV
mmol/1 (%) (%) (%) (%)
Glucose
Without carryover
Path-L 1.465
Well-I 6.257
Geo A 632 26.068
With carryover
Path-L 1.470
Well-I 6.293
Geo A 632 26.063
Urea
Without carryover
Path-L 2.961
Well-I 9.095
Geo A 632 31.761
With carryover
Path-L 2.956
Well-I 9.069
Geo A 632 31.777
* Carryover effect at ot.O1 level
0.0226 1.54 (80) 0.0116 0.79 (20) 0.0690 4.71 (19) 0.0735
0.0868 1.39 (80) 0.0233 0.37 (20) 0.0800 1.28 (19) 0.1204
0.1834 0.70 (90) 0.0992 0.38 (20) 0.4142 1.59 (19) 0.4637
0.0253 1.72 (80) 0.0165 1.12 (20) 0.0683 4.65 (19) 0.0747
0.1296" 2.06 (80) 0.0 0.00 (20) 0.1158 1.84 (19) 0.1712
0.1579 0.61 (80) 0.1200 0.46 (20) 0.4091 1.57 (19) 0.4547
0.0378 1.28 (79) 0.0266 0.90 (20) 0.1120 3.78 (19) 0.1210
0.1215 1.34 (80) 0.0562 0.62 (20) 0.1377 1.51 (19) 0.1920
0.4851 1.53 (80) 0.0 0.00 (20) 0.2719 0.86 (19) 0.5561
0.0327 1.11 (80) 0.0194 0.66 (20) 0.1152 3.90 (19) 0.1214
0.1842" 2.03 (80) 0.1123 1.24 (20) 0.1201 1.32 (19) 0.2469
0.4856 1.53 (80) 0.1289 0.48 (20) 0.2085 0.66 (19) 0.5439
(dr)
5.02 (119)
1.92 (119)
1.78 (119)
5.08 (119)
2.72 (119)
1.74 (119)
4.09 (118)
2.11 (119)
1.75 (119)
4.11 (119)
2.72 (119)
1.71 (119)
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Fluoride oxalate plasma was used for glucose estimation.
Care must be taken to ensure that plasma samples are
obtained from blood samples which had the recommended
amounts of anticoagulant added. High concentrations of
anticoagulant resulting from inadequate filling of a specimen
container could adversely affect measurement by a test or
comparative method [3 ].
The choice and control of the comparative method
represents the second major problem in the comparison of
methods experiment and whereas the protocol discusses
briefly the factors affecting the choice of a comparative or
reference method it does not provide guidance as to the
control of that method during the period of study. The data
presented in Table 6 represents an attempt to provide some
information about the bias of the comparative methods with
reference to their overall and method means. It can be seen
that the comparative method for urea shows a significant
proportional error of the order of +5% when compared
against overall mean values which may account in part for
the significant proportional error of approximately-5% for
the Kodak results against the comparative results using
patient samples.
In the preparation of accuracy performance claims it is
clear that calculation of bias is dependent on reliable
estimates of slope and intercept and that the tolerance
limits are additionally dependent on the standard error about
the regression line (Syx).
Preparation of data in the manner recommended will
sometimes lead to a reduction in the range of samples
analysed and additionally the removal of outliers will reduce
the value of Syx. For performance claims to be comparable
these factors must be taken into account. These effects are
discussed in detail elsewhere [8]. The protocol suggested
that tolerance limits and total error be calculated only for
medical decision concentrations closest to the mean of the
comparative method data (x). Table 5 shows that for glucose
this requirement is reasonably well fulfilled. For the medical
decision concentration of 6.6 mmol/1 the value of the mean
of x was 7.1. However for urea the situation was less than
satisfactory with a mean value of x of 7.8 and a medical
decision concentration of 9.60 mmol/1. This problem has
however already appeared in the literature 9] with a medical
decision concentration of 1100 mg/1 (6.2 mmol/1) for glucose
having tolerance limits and total,error quoted when the means
of comparative or reference methods were 1670 mg/1 (9.3
mmol/1) and 1600 mg/1 (9.0 mmol/1) respectively and for a
medical decision concentration of 250 mg/1 (8.9 mmol/1)
for urea nitrogen with a comparative method mean at 512
mg/1 (18.3 mmol/1). It will be necessary to indicate how
close is close if performance claims are to be of value and be
comparable. The mean of the comparative method (x) should
be given in an accuracy performance claim in order to avoid
misunderstanding.
The proposed standard, PSEP-4, would be improved by
inclusion of some basic criteria for evaluation of the com-
parative method against other laboratories in the form of
method means. It is in this area that manufacturers are most
vulnerable to claims made for or against their products by
laboratories using inadequately controlled comparative or
reference techniques.
Table 5. Accuracy performance claims at selected medical decision concentrations
Medical decision Mean Bias
Chemistry level Xc (mmol/1)* of X Yc** )c"c
Tolerance limits Est of total error
Yc -+ K (Syx) KSyx (c" c)
Glucose 2.8 2.6 0.2
5.6 5.4 0.2
6.6 7.1 6.4 0.2
Urea 9.6 7.8 8.9 0.7
5.7 to 7.1 0.9
7.8 to 10.0 1.8
K Tolerance factor for Y O. 99 p O. 96 [10]
* Barnet (1968)
** Based on data set e3
Table 6. Comparison studies between Kodak and AutoAnalyzer with overall and method means for Burroughs Wellcome
Quality Control sera (N 12, mean of pairs)
Range SD SD Corr SDx
x y (mmol/1) Slope slope Intercept intercept Syx coeff Syx
Glucose
(a)
mean of AA mean of Kodak 3.30-13.85 0.988 0.016 -0.088 0.145 0.222 0.9987 19.2
(b)
overall mean mean of Kodak 3.40-13.77 0.993 0.019 -0.198 0.179 0.270 0.9981 15.7
(c)
method mean mean ofAA 3.37-13.72 1.005 0.014 -0.042 0.129 0.197 0.9990 21.5
(d)
overall mean mean ofAA 3.40-13.77 1.006 0.014 -0.108 0.126 0.191 0.9991 22.1
Urea
(e)
mean of AA mean of Kodak 5.55-24.75 0.953 0.029 -0.889 0.479 0.663 0.9955 10.5
(f)
overall mean mean of Kodak 5.21-23.61 1.000 0.029 -0.893 0.457 0.633 0.9959 10.5
(g)
method mean mean ofAA 5.20-24.18 1.021 0.010 0.215 0.157 0.219 0.9996 31.2
(h)
overall mean mean ofAA 5.21-23.61
* see text for discussion ofsignificant difference
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Because of the difficulties associated with obtaining
patient samples and the labile nature of some analytes,
manufacturers will always require the assistance of clinical
chemistry laboratories in the establishment of performance
claims, but our experience suggests that this work should
not be undertaken lightly by laboratories and that manu-
facturers would be advised to assess the resources of any
chosen site carefully before proceeding.
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Welwyn Garden O’ty and St Albans City Hospital, St. Albans, Hefts, UK.
Introduction
The previous paper [2] described two method comparison
studies which followed the guidelines of the National
Committee for Clinical Laboratory Standards protocol
PSEP-4, comparison of methods experiment ]. The Kodak
Ektachem analytical system for urea and glucose was com-
pared with Technicon AutoAnalyzer methodologies. Two
hundred patient samples distributed according to PSEP-4
guidelines were analysed in duplicate by the test and com-
parative methods. Twice the minimum recommended number
of patient samples were used in order to study the effect
of sample size above as well as below the recommended
minimum number. The data for glucose is presented and the
data modified to produce changes in the sample number,
distribution and range.
The estimates of slope, intercept and standard error of the
estimate of y (Syx) from linear regression analysis are used in
the calculation of the tolerance limits and in estimates of
total error at medical decision levels, which provide a basis
for manufacturers’ performance claims. This paper illustrates
the way in which sample number, distribution and range
could alter the manufacturers’ performance claims and gives
an indication of the magnitude of these effects. The methods
adopted for detection of outliers in the data can also have a
marked effect on the claims made.
Materials and methods
Experimental methods and materials for glucose have been
described previously [2]. The distribution of patient samples
recommended for glucose analysis was Group A (<2.8
mmol/1) 10%; B (2.9-6.1 mmol/1) 40%; C (6.2-8.3 mmol/1)
30%; D (8.4-13.8 mmol/1) 10%; and Group E (>13.8 mmol/1)
10%. The information in the draft version of the PSEP-4
protocol contained a misprint and groups for glucose were
given as A (10%), B (40%), C (20%, D (10%) and E (10%). In
our experiment 20% of samples were-collected in Group E.
However, the recommended distribution and our distribution
have been compared with other possible distributions for one
hundred samples by data modification described below.
The equations for linear regression analysis were those
given in Davies et al [3]. Modification of the original data
base of two hundred samples analysed in duplicate by test
and comparative method is described below.
Range of samples
The results were divided into their five separate groups
(A-E) and modified data sets for linear regression analysis
provided by increasing range from low concentrations, A, AB,
ABC, ABCD, ABCDE and from high concentrations, E, DE,
CDE, BCDE, ABCDE and from mid concentrations, C, BCD,
ABCDE.
178 Journal of Automatic Chemistry